Gatekeeper V561M mutations as a mechanism of resistance to relapsed/refractory hematologic malignancies treated with Pemigatinib
International Journal of Cancer Care and Delivery · 2025
DOI: 10.53876/001a.129570 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer Care and Delivery, 2025. Verfasst von Andrew Palmer und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Palmer, A., Kosuri, S., Dworkin, E., & Roloff, G. (2025). Gatekeeper V561M mutations as a mechanism of resistance to relapsed/refractory hematologic malignancies treated with Pemigatinib. International Journal of Cancer Care and Delivery. https://doi.org/10.53876/001a.129570
Vancouver
Palmer A, Kosuri S, Dworkin E, Roloff G. Gatekeeper V561M mutations as a mechanism of resistance to relapsed/refractory hematologic malignancies treated with Pemigatinib. International Journal of Cancer Care and Delivery. 2025. doi:10.53876/001a.129570
BibTeX
@article{Palmer2025,
author = {Palmer, Andrew and Kosuri, Satya and Dworkin, Emily and Roloff, Gregory},
title = {Gatekeeper V561M mutations as a mechanism of resistance to relapsed/refractory hematologic malignancies treated with Pemigatinib},
journal = {International Journal of Cancer Care and Delivery},
year = {2025},
doi = {10.53876/001a.129570}
}
EUVIMED